Radiation Segmentectomy for Hepatocellular Carcinoma

Muhamad Serhal; Farnaz Dadrass; Edward Kim; Robert J. Lewandowski

doi:10.3390/curroncol31020045

Radiation Segmentectomy for Hepatocellular Carcinoma

Muhamad Serhal
, Farnaz Dadrass
, Edward Kim
, Robert J. Lewandowski

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

The application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCLC) paradigm will be highlighted. RADSEG outcomes concerning safety and efficacy will be explored and compared with traditional locoregional cancer treatments like trans-arterial chemoembolization (TACE), percutaneous thermal ablation, and surgical resection, with an eye on future directions and considerations.

Original language	English
Pages (from-to)	617-628
Number of pages	12
Journal	Current Oncology
Volume	31
Issue number	2
DOIs	https://doi.org/10.3390/curroncol31020045
State	Published - Feb 2024
Externally published	Yes

Keywords

Barcelona Clinic Liver Cancer paradigm
hepatocellular carcinoma
radiation segmentectomy
radioembolization

Access to Document

10.3390/curroncol31020045

Cite this

@article{add4c6c59bc74b5e96eabe8e0359782b,

title = "Radiation Segmentectomy for Hepatocellular Carcinoma",

abstract = "The application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCLC) paradigm will be highlighted. RADSEG outcomes concerning safety and efficacy will be explored and compared with traditional locoregional cancer treatments like trans-arterial chemoembolization (TACE), percutaneous thermal ablation, and surgical resection, with an eye on future directions and considerations.",

keywords = "Barcelona Clinic Liver Cancer paradigm, hepatocellular carcinoma, radiation segmentectomy, radioembolization",

author = "Muhamad Serhal and Farnaz Dadrass and Edward Kim and Lewandowski, \{Robert J.\}",

note = "Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = feb,

doi = "10.3390/curroncol31020045",

language = "English",

volume = "31",

pages = "617--628",

journal = "Current Oncology",

issn = "1718-7729",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

TY - JOUR

T1 - Radiation Segmentectomy for Hepatocellular Carcinoma

AU - Serhal, Muhamad

AU - Dadrass, Farnaz

AU - Kim, Edward

AU - Lewandowski, Robert J.

PY - 2024/2

Y1 - 2024/2

N2 - The application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCLC) paradigm will be highlighted. RADSEG outcomes concerning safety and efficacy will be explored and compared with traditional locoregional cancer treatments like trans-arterial chemoembolization (TACE), percutaneous thermal ablation, and surgical resection, with an eye on future directions and considerations.

AB - The application of trans-arterial radioembolization (TARE) with Yttrium-90, historically a palliative treatment option for patients with advanced hepatocellular carcinoma (HCC), is evolving. Radiation segmentectomy (RADSEG), the segmental delivery of an ablative radiation dose, is a treatment option for patients with earlier-stage HCC. This review presents an in-depth exploration of RADSEG, emphasizing its technical considerations, dosimetry advancements, and patient selection. The integration of RADSEG into the Barcelona Clinic Liver Cancer (BCLC) paradigm will be highlighted. RADSEG outcomes concerning safety and efficacy will be explored and compared with traditional locoregional cancer treatments like trans-arterial chemoembolization (TACE), percutaneous thermal ablation, and surgical resection, with an eye on future directions and considerations.

KW - Barcelona Clinic Liver Cancer paradigm

KW - hepatocellular carcinoma

KW - radiation segmentectomy

KW - radioembolization

UR - https://www.scopus.com/pages/publications/85185855893

U2 - 10.3390/curroncol31020045

DO - 10.3390/curroncol31020045

M3 - Review article

C2 - 38392039

AN - SCOPUS:85185855893

SN - 1718-7729

VL - 31

SP - 617

EP - 628

JO - Current Oncology

JF - Current Oncology

IS - 2

ER -

Radiation Segmentectomy for Hepatocellular Carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this